HIV Vaccines for Human Immunodeficiency Virus Infection
(DC-HIV04 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will be done in people living with HIV to see if an investigational vaccine made from a person's own white blood cells is safe and tolerated. This study will also look at the body's immune response to the vaccine and evaluate four different methods of making the vaccine to see which method may result in better immune responses.
Who Is on the Research Team?
Bernard Macatangay, MD
Principal Investigator
University of Pittsburgh
John Mellors, MD
Principal Investigator
University of Pittsburgh
Sharon Riddler, MD
Principal Investigator
University of Pittsburgh
Are You a Good Fit for This Trial?
Adults aged 18-70 with stable HIV infection, on continuous ART for at least 24 months, and undetectable viral load for over two years. They must have good organ function, not be pregnant or breastfeeding, agree to use contraception if necessary, and have no history of certain chronic conditions or recent hospitalizations.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Step 1
Participants undergo initial tests, procedures, and exams. Randomization into study groups occurs at Week 4.
Step 2
Participants receive 6 study vaccinations at 4-week intervals and are monitored for health, safety, and immune response.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- a1DC + conserved HIV peptides
- a1DC + inactivated whole autologous HIV
- a1DC + no antigen
- pgDC + conserved HIV peptides
- pgDC + inactivated whole autologous HIV
- pgDC + no antigen
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sharon Riddler
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator